This first of two back-to-back GEN reports tells you what's trending in this expanding space.!--h2>
This GEN Market & Tech Analysis report is the first of two reports designed to frame some of the market trends operative in the personalized medicine field.
Highlights of this report:
We have utilized primary and secondary market research to characterize the expanding personalized medicine space.
Cancer personalized medicine dominates the space currently, but other disease classes such as infectious disease, cardiovascular, and CNS diseases are making inroads.
Currently the top biomarker class is based on protein expression patterns; this includes immunoassays and other protein analyte characterization methodologies.
We believe that over time the field will expand to include other biomarker classes—both tissue-based biomarkers as well as circulating biomarkers.
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at [email protected].